Clinical Trials Browser

Phase 2 × Interventional × GSK2256098 × Clear all

NCT02523014 2026-03-04

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Phase 2 Recruiting

Meningioma

NCT02428270 2022-11-01

A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms